<code id='11C1957B03'></code><style id='11C1957B03'></style>
    • <acronym id='11C1957B03'></acronym>
      <center id='11C1957B03'><center id='11C1957B03'><tfoot id='11C1957B03'></tfoot></center><abbr id='11C1957B03'><dir id='11C1957B03'><tfoot id='11C1957B03'></tfoot><noframes id='11C1957B03'>

    • <optgroup id='11C1957B03'><strike id='11C1957B03'><sup id='11C1957B03'></sup></strike><code id='11C1957B03'></code></optgroup>
        1. <b id='11C1957B03'><label id='11C1957B03'><select id='11C1957B03'><dt id='11C1957B03'><span id='11C1957B03'></span></dt></select></label></b><u id='11C1957B03'></u>
          <i id='11C1957B03'><strike id='11C1957B03'><tt id='11C1957B03'><pre id='11C1957B03'></pre></tt></strike></i>

          Home / fashion / comprehensive

          comprehensive


          comprehensive

          author:Wikipedia    Page View:12163

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In